Create Biosciences announces the completion of a reverse merger with Ikena Oncology.

On July 28th, Inmagene announced the completion of a reverse merger with Ikena Oncology, Inc. The merged company was officially renamed ImageneBio, Inc. and was listed on the Nasdaq in the United States on July 28, 2025, with the stock code "IMA". The core asset of Imagene is the OX40-targeted monoclonal antibody IMG-007, which is currently undergoing Phase 2b clinical trials for moderate to severe atopic dermatitis. With this strategic upgrade, Miragene also announced its full independent operation. In addition to IMG-007, all product pipelines, collaborative projects, and resources from the "Smart Innovation" platform under the original Inmagene will be transferred to Miragene as a whole.